Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, “eribulin”) will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.

Eisai will present five eribulin-related abstracts, including a post hoc subgroup analysis from two pivotal Phase 3 studies (EMBRACE and Study 301), as well as:

- Real world use of eribulin following treatment with a PI3K inhibitor, mostly in people with Hormone Receptor (HR)-positive/HER2-negative metastatic breast cancer.
- Preclinical data exploring a liposomal formulation of eribulin, in a Phase 1 expansion cohort for breast cancer, versus eribulin at the same dose, in patient-derived breast cancer xenografts.

“We continue to relentlessly pursue research that provides useful insights for people living with breast cancer,” said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “A big part of this commitment is the ongoing sharing of our preclinical and clinical data with eribulin.”

This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.

Eisai presentations at the 2022 SABCS are as follows:

<table>
<thead>
<tr>
<th>Product</th>
<th>Abstract No.</th>
<th>Abstract name and scheduled presentation date and time (Central Standard Time)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eribulin</td>
<td>P1-03-02</td>
<td>Efficacy of eribulin mesylate in HER2-low and HER2-0 metastatic breast cancer (MBC): Results from an analysis of two phase 3 studies Poster Session</td>
</tr>
<tr>
<td>Eribulin</td>
<td>P1-03-03</td>
<td>Real-world treatment patterns and clinical outcomes in patients treated with Eribulin after prior PI3K inhibitor therapy for metastatic breast cancer Poster Session</td>
</tr>
<tr>
<td>Eribulin</td>
<td>P3-07-03</td>
<td>Anti-tumor activity of a liposomal formulation of Eribulin compared with the same dose of Eribulin in patient-derived breast cancer xenografts Poster Session</td>
</tr>
<tr>
<td>Eribulin</td>
<td>P4-07-19</td>
<td>Eribulin enhances STING-dependent induction of type I interferons in immune and triple-negative breast cancer cells Poster Session</td>
</tr>
</tbody>
</table>
Role of tumor infiltrating lymphocytes and PD-L1 expression in the response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial

Poster Session / December 9 (Fri), 7:00-9:00AM

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

[Notes to editors]

1. Eisai’s Focus on Cancer
Eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging RNA Splicing Platform) as areas (Ricchi) where real patient needs are still unmet, and where Eisai can aim to become a frontrunner in oncology. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these Ricchi, with the aim of contributing to the cure of cancers.

###